Trinity Biotech Q3 2024 shows steady growth

Trinity Biotech Q3 2024 shows steady growth, strategic moves

Earnings call: Trinity Biotech Q3 2024 shows steady growth, strategic moves.

Trinity Biotech's Q3 2024 Revenue and Strategic Growth - Nasdaq

Trinity Biotech (TRIB) has released an update.Trinity Biotech reported a 3% increase in Q3 2024 revenue to $15.2 million, driven by strong ...

Trinity Biotech PLC (TRIB) Q3 2024 Earnings Call Highlights

Positive Points · Trinity Biotech PLC (NASDAQ:TRIB) reported a 3% year-on-year revenue growth, driven by TrinScreen HIV revenues. · The company is ...

Trinity Biotech Announces Q3 2024 Financial Results - BioSpace

Year-over-year revenue growth of 3% and continued disciplined execution on our profitability enhancing initiatives contributed to a decrease in ...

Trinity Biotech's Q3 2024 Revenue and Strategic Growth - TipRanks

Trinity Biotech (TRIB) has released an update. Trinity Biotech reported a 3% increase in Q3 2024 revenue to $15.2 million, driven by strong ...

Trinity Biotech Announces Q3 2024 Financial Results - Yahoo Finance

Q3 2024 total revenue of $15.2 million grew +3% Y/Y based on strong demand and output in the TrinScreen HIV business Point-of-Care product ...

Trinity Biotech Announces Q3 2024 Financial Results - Stock Titan

$15.2M revenue represents a modest 3.2% Y/Y growth, driven by strong Point-of-Care segment growth of 60.1% . However, clinical laboratory ...

Trinity Biotech Plc Reports Q3 2024 Revenue Growth Of 3% To ...

Trinity Biotech reported Q3 2024 revenue of $15.2 million, with a 3% year-over-year increase and strong Point-of-Care sales.

Trinity Biotech Announces Q3 2024 Financial Results

Trinity Biotech to Announce Q3 2024 Financial Results

DUBLIN, Ireland, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB) (the "Company"), a commercial stage biotechnology ...

Trinity Biotech to Announce Q3 2024 Financial Results - Nasdaq

Trinity Biotech plc, a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, ...

Trinity Biotech to Announce Q3 2024 Financial Results

Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable ...

Trinity Biotech Reports Q3 2024 Progress and Financials

In the latest financial update, Trinity Biotech plc (NASDAQ: TRIB) released its results for the third quarter, reflecting a total revenue of ...

Investor Relations - Trinity Biotech plc

Trinity Biotech Announces Q2 2024 Financial Results

Strong demand and output in TrinScreen HIV drove a 14.0% year-on-year revenue increase and 7.7% quarter-on-quarter revenue increase. · 119% year- ...

Press Releases - Trinity Biotech plc is a public company ...

Trinity Biotech Announces Q3 2024 Financial Results. November 15, 2024 ... Trinity Biotech Welcomes Avinash Kale as Continuous Glucose Monitor Programme Director ...

Trinity Biotech Announces Q2 2024 Financial Results - Stock Titan

Trinity Biotech reports strong Q2 2024 results: 14% revenue growth, 119% surge in Point-of-Care sales ... Trinity Biotech's Q2 2024 results show ...

Trinity Stock Price Today | NASDAQ: TRIB Live - Investing.com

Trinity Biotech plc News & Analysis · Earnings call: Trinity Biotech Q3 2024 shows steady growth, strategic moves · Trinity Biotech regains Nasdaq compliance.

$TRIB Trinity Biotech Announces Increased Orders for TrinScreen ...

$TRIB Trinity Biotech Announces Increased Orders for TrinScreen HIV and Raises Guidance For 2024 Sales · Comments Section · Community Info Section.

Trinity Biotech Announces Q1 2024 Financial Results and

39% quarter on quarter increase in revenue from our PoC portfolio driven by increased sales of our new TrinScreen HIV product. · Successful ramp ...